On October 13, 2025, GMO launched its latest ETF, GMO Dynamic Allocation ETF (GMOD). The ETF is managed by Co-Heads of Asset Allocation Ben Inker and John Thorndike, and attracts on GMO’s proprietary 7-12 months Asset Class Forecasts. It is going to sometimes vary between 40% and 80% fairness publicity and may make investments broadly throughout shares and bonds, not restricted by sector, market cap, credit score high quality, or geography.
This may be an fascinating however distinctly contrarian operation. The hot button is that GMO has a robust and well-founded perception that asset costs can diverge meaningfully from their true worth however mean-revert to honest worth over time. Known as “imply reversion,” the thought is classically contrarian: dynamically enhance publicity to the asset lessons which can be probably the most attractively priced whereas deemphasizing people who the staff views as costly. These judgments are embodied within the staff’s broadly learn and broadly criticized 7-12 months Asset Class Forecasts, with the portfolio’s exposures actively adjusted in response to shifts in GMO’s outlook on returns, dangers, and market valuations. The issue is that irrational valuations have been extremely sticky, which signifies that imply reversion has not been occurring throughout the restrict of most traders’ persistence.
At present, the staff studies, “we’re de-emphasizing US and progress equities the place we consider that valuations are stretched, whereas being very completely happy to carry non-US and worth equities that are buying and selling at favorable valuations … Given the precarious valuations that the US and Progress have been pushed to, that is, we consider, precisely the suitable time to be investing with somebody who will not be afraid to take contrarian positions. We’re tremendously excited in regards to the outlook for potential relative alpha.”
Buyers can get some steering in regards to the seemingly trajectory of the ETF by trying on the efficiency of the 30-year-old GMO International Asset Allocation Fund, which follows the identical logic and which, the staff permits, is “the closest benchmark to GMO’s new GMOD ETF and thus probably the most pertinent benchmark.”
GMO studies that “Since inception, 22 October 1996, the Fund (6.95% APR) has overwhelmed its index (6.21%) by 74 bps per yr. We present figures versus our customized benchmark, not the Lipper peer group.” Towards the Lipper “versatile portfolio” peer group, the fund has trailed its friends by 50 bps since inception, however with dramatically much less volatility.
GMO International Asset Allocation Fund vs Lipper “versatile portfolios”
| 3 yr | 5 yr | 10 yr | 20 yr | Lifetime | |
| APR | 15.2 | 8.5 | 6.4 | 5.9 | 7% |
| APR vs friends | 3.1 | 0.1 | -0.6 | -0.7 | -0.5% |
| Sharpe vs friends | 0.36 | 0.3 | -0.4 | 0.2 | -0.1 |
| Draw back vs friends | 1.2% higher | 0.5% higher | 0.5% higher | 1.6% higher | 0.6% higher |
| Most drawdown | 1.9% higher | 3.1% worse | 1.1% worse | 8.8% higher | 7.9% higher |
Supply: MFO Premium fund screener and Lipper International Datafeed
On the entire, the technique has been constantly aggressive when it comes to complete return, has had constantly much less draw back (measured by draw back deviation and most drawdown), and has had barely higher risk-adjusted returns. That appears broadly in keeping with Morningstar’s threat and return metrics as effectively. As well as, the fund’s three-year document has been exceptionally robust because the stranglehold of US + Progress has weakened.
GMO’s ETF lineup additionally consists of QLTY (U.S. High quality), QLTI (Worldwide High quality), GMOV (U.S. Worth), GMOI (Worldwide Worth), BCHI (Past China), DRES (Home Resilience), and INVG (Systematic Funding Grade Credit score).
The fund will cost 0.50%.
Backside line: GMO may be very, very disciplined. If market behaviors start to normalize – which is to say, that issues like revenue margins or valuations revert to their means and markets will not be inexplicably dominated by simply 5 to 10 firms – that self-discipline, GMOs analysis, and their lengthy document with multi-asset portfolios is prone to serve traders effectively.
